What is HC Wainwright’s Estimate for TNYA Q3 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Tenaya Therapeutics in a report released on Thursday, August 6th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.09) per share for the quarter. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ Q4 2026 earnings at ($0.10) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $7.50 million.

Several other equities analysts have also weighed in on the company. Wall Street Zen lowered Tenaya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings upgraded Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

Tenaya Therapeutics Stock Performance

Shares of Tenaya Therapeutics stock opened at $0.73 on Friday. The firm has a 50-day simple moving average of $0.77 and a two-hundred day simple moving average of $0.76. Tenaya Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $2.35. The company has a market cap of $157.50 million, a P/E ratio of -1.37 and a beta of 2.83.

Institutional Investors Weigh In On Tenaya Therapeutics

A number of large investors have recently modified their holdings of the business. Integrity Wealth Solutions LLC purchased a new stake in shares of Tenaya Therapeutics during the first quarter worth $27,000. Scientech Research LLC purchased a new position in shares of Tenaya Therapeutics in the third quarter worth about $27,000. Comerica Bank acquired a new position in Tenaya Therapeutics during the first quarter worth about $50,000. Cerity Partners LLC boosted its position in Tenaya Therapeutics by 403.5% during the second quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock worth $67,000 after acquiring an additional 88,424 shares during the last quarter. Finally, Corient Private Wealth LLC acquired a new position in Tenaya Therapeutics during the fourth quarter worth about $72,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno?associated virus (AAV) platform, the company aims to deliver durable, one?time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.